Yarrow Bioscience (YARW)

Executive Summary

Yarrow Bioscience is a private biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing novel antibody therapeutics for thyroid autoimmune diseases, with its lead asset YB-101 targeting the TSH receptor (TSHR) for both Graves' disease and thyroid eye disease (TED). Graves' disease is an autoimmune condition causing hyperthyroidism, while TED is a debilitating orbital inflammation often associated with it. YB-101 is positioned as a first-in-class anti-TSHR antibody, potentially addressing a significant unmet need given the limited treatment options for TED and the side effects of current therapies. The company operates in the competitive antibody therapeutics space but leverages a unique target and disease focus. As a private entity, Yarrow has not disclosed funding rounds or valuation, indicating an early-stage profile. Its success hinges on advancing YB-101 through preclinical and clinical development, demonstrating safety and efficacy in thyroid autoimmune indications.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for YB-101 in Graves' Disease60% success
• Q1 2027Initiation of Phase 1 Clinical Trial for YB-10150% success
• Q3 2026Publication of Preclinical Data for YB-101 in Thyroid Eye Disease70% success